Cargando…

MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexiform neurof...

Descripción completa

Detalles Bibliográficos
Autor principal:	Harder, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052700/ https://www.ncbi.nlm.nih.gov/pubmed/33863389 http://dx.doi.org/10.1186/s40364-021-00281-0

Ejemplares similares

Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
por: Sweeney, Elizabeth E., et al.
Publicado: (2016)

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
por: Armstrong, Amy E., et al.
Publicado: (2023)

ETS-targeted therapy: can it substitute for MEK inhibitors?
por: Tetsu, Osamu, et al.
Publicado: (2017)

Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1
por: Cantor, Evan, et al.
Publicado: (2022)

Radiofrequency for benign and malign thyroid lesions
por: Rangel, Leonardo, et al.
Publicado: (2020)

Role of metallothioneins in benign and malignant thyroid lesions
por: Pula, Bartosz, et al.
Publicado: (2012)

MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro
por: Fischer-Huchzermeyer, Susan, et al.
Publicado: (2017)

Computed Tomography–Based Differentiation of Benign and Malignant Craniofacial Lesions in Neurofibromatosis Type I Patients: A Machine Learning Approach
por: Wei, Cheng-Jiang, et al.
Publicado: (2020)

Diagnostic Snapshot: Aggressive Malignancy or Benign Lesion?
por: Goforth, Paige M.
Publicado: (2014)

Subclinical granulomas in benign skin lesions heralding the onset of BRAF and MEK inhibitor–associated granulomatous dermatitis in a patient with metastatic melanoma
por: Korman, Abraham M., et al.
Publicado: (2018)

Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy
por: Li, Yanan, et al.
Publicado: (2019)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors
por: Williams, Kyle B., et al.
Publicado: (2020)

Do non-pathogenic variants of DNA mismatch repair genes modify neurofibroma load in neurofibromatosis type 1?
por: Harder, Anja
Publicado: (2022)

Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
por: Liu, Jun, et al.
Publicado: (2022)

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
por: Nucera, Carmelo
Publicado: (2019)

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function
por: Principe, D R, et al.
Publicado: (2017)

FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy
por: Voigt, Ellen, et al.
Publicado: (2023)

The Role of EUS and EUS-FNA in Differentiating Benign and Malignant Gallbladder Lesions
por: Hijioka, Susumu, et al.
Publicado: (2021)

Malignant transformation of plexiform neurofibroma to MPNST while on MEK inhibitor
por: Fasih, Samir, et al.
Publicado: (2021)

Genes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions
por: Adzavon, Yao Mawulikplimi, et al.
Publicado: (2018)

Current progress in genomics and targeted therapies for neurofibromatosis type 2
por: Hiruta, Ryo, et al.
Publicado: (2023)

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
por: Tran, Khiem A, et al.
Publicado: (2015)

MEK and the inhibitors: from bench to bedside
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Panniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect
por: Negulescu, Miruna, et al.
Publicado: (2017)

Calcified or ossified benign soft tissue lesions that may simulate malignancy
por: Kwee, Robert M., et al.
Publicado: (2019)

Imaging evaluation of the benign and malignant lesions of the floor of the mouth: Pictorial review
por: Lahiri, Ashim K., et al.
Publicado: (2023)

Vulvar Malignancy in Neurofibromatosis Syndrome
por: Musella, Angela, et al.
Publicado: (2013)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

Neurofibromatosis Type 1 Gene Alterations Define Specific Features of a Subset of Glioblastomas
por: Scheer, Maximilian, et al.
Publicado: (2021)

The Detection and Association of Canine Papillomavirus with Benign and Malignant Skin Lesions in Dogs
por: Chang, Chia-Yu, et al.
Publicado: (2020)

Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study
por: Seminog, O O, et al.
Publicado: (2013)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Glutathione localisation in benign and malignant human breast lesions.
por: Murray, G. I., et al.
Publicado: (1987)

Caveolin-1 expression in benign and malignant lesions of the breast
por: Liedtke, Cornelia, et al.
Publicado: (2007)

BENIGN AND MALIGNANT SKIN LESIONS IN RENAL TRANSPLANT RECIPIENTS
por: Ghaninejad, H, et al.
Publicado: (2009)

Benign, Premalignant, and Malignant Lesions Encountered in Bariatric Surgery
por: Raghavendra, Rao S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2vs0ru0etfkfasrd2o9sh9o051